A recent study published by the American Association for Cancer Research found that nicotine at doses similar to those found in most nicotine replacement therapies did not increase lung cancer tumor incidence, frequency or size. The researchers concluded that nicotine replacement therapy is probably a safe option.
Researchers found significantly higher rates of HPV antibodies in people with lung cancer compared to those without the disease. High-risk types of HPV were particularly prevalent, suggesting a potential link between HPV infection and lung cancer development.
Research reveals that people with AIDS have a significantly higher risk of developing stomach and esophageal malignancies, including a 6.9-fold increased incidence of stomach cancer and a 2.7-fold increased risk of esophageal cancer compared to the general population.
A study published at the AACR Annual Meeting found that women with ovarian cancer and BRCA2 mutations had improved survival rates compared to those with BRCA1 mutations or no mutations. The five-year survival rate for women with BRCA2 mutations was 61%, significantly higher than those without mutations (36%). Further research is needed...
Researchers found a potential target for treating squamous cell lung cancer by identifying a DDR2 gene mutation that responds to dasatinib treatment. Approximately one in two thousand people in the US annually carry this mutation, and tumor cells with it showed significant response to dasatinib, indicating a new targeted therapy option.
A multidisciplinary team identified digoxin as a possible therapy for prostate cancer through drug repositioning. Regular digoxin use reduced the risk of prostate cancer by 24% and 46% for long-term users, respectively.
Researchers have identified an oncogenic gene fusion of KRAS in a metastatic prostate cancer cell line, shedding light on the genetic characteristics of this disease. This finding may enable better prognostic information to separate slow-growing tumors from aggressive ones, ultimately improving treatment strategies.
A recent study published in the American Association for Cancer Research found that smoking did not affect breast cancer risk among obese postmenopausal women. In contrast, non-obese women with a history of smoking had a significantly higher risk for breast cancer.
Researchers found that individuals with metabolic syndrome are at higher risk for developing liver cancers, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma. The study, presented at the AACR 102nd Annual Meeting, highlights the importance of metabolic syndrome in increasing liver cancer incidence.
A study found that diabetes is associated with a lower risk of prostate cancer in men, but a higher risk of other cancers and mortality in both men and women. Diabetes was linked to increased risks for colon, rectal, and liver cancers in men and women.
Researchers found that macrophage and T-cell levels can predict recurrence and survival in breast cancer. A new therapy targeting macrophages shows promising results in preclinical studies.
The American Association for Cancer Research is prioritizing clinical trials to advance cancer treatment and prevention. Researchers presented findings on basal cell cancer and lung cancer, highlighting the potential of biomarkers and hedgehog pathway inhibitors. New discoveries aim to improve patient outcomes and reduce side effects.
A new hedgehog pathway inhibitor, GDC-0449, demonstrated efficacy in preventing and treating basal cell cancer among patients with basal cell nevus syndrome. The drug reduced the development of new lesions and decreased tumor size, offering a promising treatment option for these patients.
Researchers testing a combination of GDC-0973 and GDC-0941, which inhibit the RAS/RAF/MEK and PI3K pathways, report encouraging safety data and early signs of anti-tumor activity. Patients with various types of cancer have shown decreases in tumor size, suggesting potential benefits for targeted therapy.
Researchers sequenced whole genomes of tumors from 50 breast cancer patients and compared them to healthy cells, finding over 1,700 unique mutations. The study identified three significant mutations that may be common in ER-positive breast cancers, offering new avenues for personalized treatment.
A genetic variant has been linked to both longer telomeres and a reduced risk of bladder cancer, according to researchers. The study found that the variant, rs398652, was associated with a 19% reduction in bladder cancer risk.
Researchers have identified a biomarker for measuring the success of lung cancer chemoprevention, using abnormal cell development (endobronchial dysplasia). The study found that measurements of endobronchial dysplasia can predict how well a chemoprevention agent is working in former smokers.
Researchers at the BATTLE trial have identified two novel gene markers, including an EMT signature and LCN2, that predict response to EGFR inhibition in patients with wild-type EGFR. These biomarkers may help identify patients who can benefit from erlotinib treatment.
A study found that improved quality of life and reduced stress response were associated with changes in telomere length in cancer patients. Psychological counseling had a potential impact on modulating telomere length, but the findings require further exploration.
Researchers have found a new method for detecting prostate cancer that analyzes non-tumor tissue, potentially improving diagnosis accuracy. This approach could help reduce the number of repeat biopsies and improve patient outcomes.
Dr. Yosef Shiloh is recognized for his groundbreaking work on ataxia-telangiectasia (A-T), a rare disease caused by a defect in the cellular response to DNA damage. His identification of the ATM gene has revolutionized the field, leading to significant advances in our understanding of DNA damage response and repair.
The American Association for Cancer Research (AACR) has recognized 24 new grant recipients for their groundbreaking research in cancer treatment and prevention. These grants support innovative projects focused on invasive bladder cancer, ovarian cancer, skin tumorigenesis, tumor microenvironment, head and neck cancer radiation response...
The American Association for Cancer Research (AACR) has awarded 27 undergraduate students with the AACR-Thomas J. Bardos Science Education Award, recognizing their dedication to advancing cancer research. The award aims to inspire science students at the undergraduate level to pursue careers in cancer research.
The Pancreatic Cancer Action Network and AACR have awarded Jennifer M. Bailey and E. Scott Seeley $600,000 grants to pursue groundbreaking research on pancreatic cancer initiation and progression. Their projects focus on novel insights into KRAS mutations and transport proteins as modifiers of oncogenic signaling.
The American Association for Cancer Research has awarded 50 Minority Scholar in Cancer Research Awards to early-career scientists from diverse backgrounds. The recipients, who were chosen based on their qualifications and potential impact, will receive funding and support to attend the annual meeting and present their research.
The American Association for Cancer Research has awarded grants to researchers studying carcinoid tumors and pancreatic neuroendocrine tumors. These grants will support the development of new treatments and therapies for these cancers, including those targeting the menin-regulated signaling pathway and oncolytic viral therapy.
Pier Paolo Pandolfi has made significant contributions to cancer research, particularly in the area of leukemia treatment. His work on mouse models and chromosomal translocations has led to the development of novel therapeutic strategies, making APL a curable disease.
The Pancreatic Cancer Action Network and the American Association for Cancer Research awarded 10 grants totaling nearly $3 million to support innovative pancreatic cancer research. The recipients will be honored at the AACR Annual Meeting, with a focus on building a comprehensive and coordinated pancreatic cancer research community.
Susan Band Horwitz, a renowned molecular pharmacologist, receives the Eighth Annual AACR Award for Lifetime Achievement in Cancer Research. Her pioneering work on paclitaxel has led to significant advancements in cancer treatment, particularly in ovarian, breast, and lung carcinomas.
The American Association for Cancer Research and the Landon Foundation will present three INNOVATOR Awards to recognize emerging mid-career researchers. The awards support innovation in cancer prevention, international collaboration, and personalized medicine research.
The American Association for Cancer Research (AACR) recognizes leaders in the minority cancer community with the Minority-Serving Institution Faculty Scholars in Cancer Research Awards. The awards aim to increase scientific knowledge, encourage research, and inspire students to pursue careers in cancer research.
A team of international researchers from Fred Hutchinson Cancer Research Center and University of Washington have made significant contributions to understanding human papillomavirus (HPV) infections. They developed the HPV vaccine, which has the potential to prevent over half a million HPV-associated cancers worldwide.
Dr. Arthur D. Levinson is recognized for his leadership and extraordinary achievements in cancer research, leading to targeted drugs and personalized healthcare. He was a key figure in developing cancer therapeutics, including Herceptin, Avastin, and Rituxan.
The American Association for Cancer Research (AACR) is honoring two renowned cancer researchers, Helen Blau and Nathanael Gray, for their groundbreaking contributions to the field. Helen Blau's work on regenerative medicine and cellular plasticity has led to new approaches in modeling diseases and regenerating damaged tissues.
Susan Band Horwitz has made significant contributions to cancer research, including the discovery of paclitaxel's mechanism of action and its role in treating various cancers. Her work on microtubules and drug resistance continues to advance our understanding of cancer treatments.
A team of internationally recognized molecular biologists, epidemiologists, and clinicians have been honored for their groundbreaking work on human papillomavirus (HPV) research. Their collaborative efforts have led to significant advances in understanding HPV's role in cancer development and the development of the HPV vaccine.
Yosef Shiloh, a renowned expert in ataxia-telangiectasia (A-T) research, has been awarded the 51st Annual AACR G.H.A. Clowes Memorial Award for his groundbreaking work on cellular DNA damage response and A-T. His discoveries have significantly advanced our understanding of this rare genomic instability syndrome.
Researchers found that estrogen induces the expression of CYP1B1 enzyme in precancerous cells, which promotes their movement and division. Depleting CYP1B1 reduces cell mobility and death in precancerous cells.
Researchers identified significant effects of different treatment options on infant outcomes, including higher rates of congenital malformations in premature deliveries. The study suggests that pregnant women with breast cancer should continue their pregnancy and receive standard treatment recommendations.
A study found that higher co-payments increase the chance of early discontinuation and inadequate use of breast cancer therapy, particularly among older women. Co-payments above $90 were associated with a higher risk of discontinuation in both younger and older age groups.
A combination of lapatinib, trastuzumab, and paclitaxel significantly improved tumor response rates compared to single-agent treatments in patients with HER2-positive breast cancers, according to early data from the NeoALTTO Trial. The study suggests that dual blockade against HER2 is an efficient way to target HER2-positive tumors.
Researchers investigating bevacizumab's efficacy in early breast cancer report promising results, with a higher pathological complete response rate compared to chemotherapy alone. The study, which included over 1,900 patients, will provide valuable insights into the effectiveness of bevacizumab as an adjuvant treatment.
A study found that high circulating tumor cells (CTCs) are an independent prognostic marker for poor overall survival in metastatic breast cancer patients undergoing first-line chemotherapy. Persistence of high CTC levels during therapy was also an early marker of poor outcome.
A Phase III study compared the efficacy of neoadjuvant therapy with lapatinib or trastuzumab in combination with chemotherapy for patients with early breast cancer. The study, conducted at 85 centers in Germany, included 2,500 patients and found similar results between the two treatment groups.
Denosumab was found to delay the time to first skeletal-related event by 18% and the time to first and subsequent event by 22%, while overall survival and disease progression were similar between groups. The treatment also showed a lower rate of jaw osteonecrosis compared to zoledronic acid.
A study published by the American Association for Cancer Research found that circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients are associated with an increased risk of relapse and death. The presence of CTCs is predicted to be a significant predictor for disease-free and overall survival.
A Phase II study found that the combination of pertuzumab and trastuzumab had superior antitumor activity, eradicating 46% of tumors in patients with early HER2-positive breast cancer. The treatment also showed promise in eliminating tumors without chemotherapy in 17% of cases.
Researchers found that CTCs in blood before chemotherapy and after transplant are associated with reduced survival and faster recurrence. The study adds insights into how hematopoietic progenitor cells recruit CTCs from bone marrow, which may be responsible for cancer recurrence.
A study published at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium found that hormone replacement therapy (HRT) with estrogen alone can reduce breast cancer risk in certain women. The analysis of data from the Women's Health Initiative (WHI) trials showed a significantly reduced breast cancer incidence in subsets of wom...
The AZURE trial, involving 3,360 patients, explores the effects of zoledronic acid on disease-free survival and secondary outcomes in Stage II/III breast cancer. The results will provide valuable insights into the benefits of combining zoledronic acid with adjuvant endocrine therapy.